BMY.TO Bristol-Myers Squibb CDR (CAD Hedged)

Healthcare Drug Manufacturers - General Toronto Exchange
22.73 CAD
Close of Nov 7, 2026
22.36 23.59
Market cap
CAD 46.4B
P/E
14.0x
P/B
5.57x
ROE
46.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BMY.TO undervalued?

Graham number
Price22.73
Graham value12.22
Premium85.9%

BMY.TO trades 85.9% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bristol-Myers Squibb CDR (CAD Hedged) fundamental analysis

No fundamental analysis for Bristol-Myers Squibb CDR (CAD Hedged) yet.

Bristol-Myers Squibb CDR (CAD Hedged) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bristol-Myers Squibb CDR (CAD Hedged)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresecta…

Full company profile